Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021-Reference-Cited by-同舟云学术

Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

Published:2021-04-22 Issue:16 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Funk Tjede¹^ORCID,Pharris Anastasia¹,Spiteri Gianfranco¹,Bundle Nick¹,Melidou Angeliki¹,Carr Michael²³,Gonzalez Gabriel²³,Garcia-Leon Alejandro⁴,Crispie Fiona⁵,O’Connor Lois⁶,Murphy Niamh⁶,Mossong Joël⁷,Vergison Anne⁷,Wienecke-Baldacchino Anke K.⁸,Abdelrahman Tamir⁸,Riccardo Flavia⁹,Stefanelli Paola⁹,Di Martino Angela⁹,Bella Antonino⁹,Lo Presti Alessandra⁹,Casaca Pedro¹⁰,Moreno Joana¹⁰,Borges Vítor¹¹,Isidro Joana¹¹,Ferreira Rita¹¹,Gomes João Paulo¹¹,Dotsenko Liidia¹²,Suija Heleene¹²,Epstein Jevgenia¹²,Sadikova Olga¹²,Sepp Hanna¹²,Ikonen Niina¹³,Savolainen-Kopra Carita¹³,Blomqvist Soile¹³,Möttönen Teemu¹³,Helve Otto¹³,Gomes-Dias Joana¹,Adlhoch Cornelia¹^ORCID,

Affiliation:

1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

2. International Collaboration Unit, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan

3. National Virus Reference Laboratory (NVRL), University College Dublin, Dublin, Ireland

4. Centre for Experimental Pathogen Host Research, University College Dublin, Dublin, Ireland on behalf of the All Ireland Infectious Diseases (AIID) Cohort

5. Teagasc Food Research Centre, Moorepark, Fermoy, Ireland on behalf of the Irish Coronavirus Sequencing Consortium (ICSC)

6. Health Service Executive - Health Protection Surveillance Centre (HPSC), Dublin, Ireland

7. Health Directorate, Findel, Luxembourg

8. National Health Laboratory, Dudelange, Luxembourg

9. Istituto Superiore di Sanità, Rome, Italy

10. Directorate of Analysis and Information, Directorate-General of Health, Lisbon, Portugal

11. Bioinformatics Unit, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal

12. Health Board, Tallinn, Estonia

13. Finnish Institute for Health and Welfare (THL), Department of Health Security, Helsinki, Finland

Abstract

We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0–2.9; B.1.351: 3.6, 95% CI: 2.1–6.2; P.1: 2.6, 95% CI: 1.4–4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4–3.5; P.1: 2.2, 95% CI: 1.7–2.8).

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference18 articles.

Cited by 227 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients;Medicina Clínica (English Edition);2024-09

2. Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden;Infectious Disease Modelling;2024-09

3. The Clinical Severity of COVID-19 Variants of Concern: Retrospective Population-Based Analysis;JMIR Public Health and Surveillance;2024-08-27

4. Focus, vigilance, resilience: towards stronger infectious disease surveillance, threat detection and response in the EU/EEA;Eurosurveillance;2024-08-22

5. The possibility of predicting the COVID-19 severity by clinical-laboratory criteria taking into account the SARS-CoV-2 strain: An analytical review;Epidemiology and Infectious Diseases;2024-07-28